Stock Picking Wins This Week
June 12, 2021
Aducanumab Approval...Implications For INmune Bio
June 8, 2021
Resetting Expectations for TFF Pharma
May 28, 2021
Reversal of Fortune
May 22, 2021
Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
May 12, 2021
The Beatings Will Continue Until Morale Improves...
May 7, 2021
Lantern Shines During Biotech Blackout
May 4, 2021
XPro1595: A Next-Generation TNF Inhibitor
April 21, 2021
2nd Degree of Risk
March 27, 2021
All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.
For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.